The rapidly growing field of cell and gene therapy is both exciting and confusing to many, including those who work in the medical community and on the periphery. Advancements of therapies happen at a feverish pace. The number of clinical trials increases exponentially in a short time. And bringing therapies to commercialisation remains a hurdle.
In a recent article in International Biopharmaceutical Industry (IBI) Magazine, Vince Paolizzi, Director of NanoCool Sales at Peli BioThermal, shares his insights into the cell and gene therapy market. He discusses the market growth, how the supply chain differs from traditional pharmaceutical supply chains, the importance of temperature and location monitoring, and what type of cold chain standardisation is needed as therapies move to commercialisation.
Read the full article starting on page 37 of this month’s IBI Magazine.